Epigenetic reprogramming with antisense oligonucleotides enhances the effectiveness of androgen receptor inhibition in castration-resistant prostate cancer

Advanced prostate cancer initially responds to androgen deprivation therapy (ADT), but the disease inevitably recurs as castration-resistant prostate cancer (CRPC). Although CRPC initially responds to abiraterone and enzalutamide, the disease invariably becomes non-responsive to these agents. Novel...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Res
Hlavní autoři: Xiao, Lanbo, Tien, Jean C., Vo, Josh, Tan, Mengyao, Parolia, Abhijit, Zhang, Yajia, Wang, Lisha, Qiao, Yuanyuan, Shukla, Sudhanshu, Wang, Xiaoju, Zheng, Heng, Su, Fengyun, Jing, Xiaojun, Luo, Esther, Delekta, Andrew, Juckette, Kristin M., Xu, Alice, Cao, Xuhong, Alva, Ajjai S, Kim, Youngsoo, MacLeod, A. Robert, Chinnaiyan, Arul M.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2018
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6191320/
https://ncbi.nlm.nih.gov/pubmed/30135193
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-18-0941
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky